

Leaders in Laboratory Medicine

Laboratory Bulletin

DATE:	2022 July 11
TO:	All Oncologists and Pathologists in Alberta
FROM:	Anatomical Pathology Discipline Council
RE:	Changes to Oncotype Dx Ordering

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- The indication for Oncotype Dx testing has been expanded to include HR-positive, HER2-negative breast cancer with macrometastases in 1-3 axillary lymph nodes.
- The OncoType DX Requisition #21809 will be updated to reflect this change and will be available on the Alberta Precision Laboratories website: Requisitions | Alberta Precision Laboratories (albertaprecisionlabs.ca)

How this will impact you

- Current/no change: Oncotype Dx may be ordered by an Oncologist or designate.
- **New**: Criteria for ordering has been **expanded** to include HR-positive, HER2-negative breast cancer with macrometastases in 1-3 axillary lymph nodes.
- Current resources are being revised to reflect the above change and will be available shortly:
 - o Oncotype Dx™ Requisition #21809 https://www.albertahealthservices.ca/frm-21809.pdf.
 - Oncotype Dx[™] Breast Cancer Molecular Testing and Reporting Oncologist https://ahs.labgms.com/labFrame.asp?DID=30711&FLDVr=1241

Action Required

• Ensure criteria for testing is documented on the OncoType DX Requisition: Confirm Test Criteria:

Node Negative / ITC / Micromets (1-3)	Node Positive (1-3)
□ ER Pos	□ ER Pos
□ HER2 neg	□ HER2 neg
☐ Grade 2 or 3	□ Post menopausal
□ Size greater than 1 cm	

Effective July 11, 2022

Questions/Concerns

- Dr. Gilbert Bigras, Pathologist, Edmonton <u>Gilbert.Bigras@albertaprecisionlabs.ca</u> 780-492-5943
- Dr. Anna Sienko, Pathologist, Calgary <u>Anna.Sienko@albertaprecisionlabs.ca</u> 403-943-4783